News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biotech Clarus Therapeutics Files for $86 Million IPO


11/23/2010 7:28:22 AM

DOW JONES NEWSWIRES -- Clarus Therapeutics Inc. has filed plans to sell up to an estimated $86.3 million in shares in an initial public offering. The pharmaceutical company has applied for its shares to be traded on the Nasdaq Global Market under the symbol CLRS. Clarus, which is developing an oral testosterone replacement therapy called OriTex, plans to use proceeds from the IPO to pay for a Phase III trial of the product and to prepare and file papers seeking Food and Drug Administration approval for it.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES